Amneal Pharmaceuticals, Inc. (AMRX)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Amneal Pharmaceuticals, Inc. reported revenue of $3.02B, up 8.0% from the prior year. The company was profitable, with a net margin of 2.4% and a gross margin of 36.9%.
Key ratios (FY2025)
36.9%
Gross margin
13.1%
Operating margin
2.4%
Net margin
+8.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B | $1.99B | $1.63B | $1.66B | $1.03B | $1.02B |
| Cost of Revenue | $1.91B | $1.77B | $1.57B | $1.43B | $1.32B | $1.33B | $1.15B | $938.77M | $507.48M | $420.77M |
| Gross Profit | $1.11B | $1.02B | $820.57M | $784.71M | $768.97M | $628.39M | $353.00M | $716.40M | $526.18M | $597.46M |
| Operating Income | $394.10M | $249.33M | $204.37M | -$94.93M | $152.72M | $91.16M | -$248.68M | -$19.67M | $245.10M | $284.88M |
| Net Income | $72.06M | -$116.89M | -$83.99M | -$270.58M | $13.16M | $67.79M | -$603.57M | -$19.74M | $0 | $0 |
| EPS (Diluted) | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.61 | $-2.74 | $-0.16 | — | — |
| Total Assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B | $4.01B | $3.67B | $4.35B | $1.34B | — |
| Total Liabilities | — | — | — | — | — | — | — | — | $0 | — |
| Shareholders' Equity | -$70.79M | -$109.27M | $19.78M | $298.42M | $360.34M | $303.27M | $232.01M | $504.75M | $0 | — |
| Cash & Equivalents | $282.03M | $110.55M | $91.54M | $25.98M | $247.79M | $341.38M | $151.20M | $213.39M | $74.17M | $27.37M |
| Operating Cash Flow | $339.99M | $295.10M | $345.58M | $65.10M | $241.82M | $379.00M | $1.71M | $250.23M | $234.19M | $115.06M |
| Capital Expenditures | $70.06M | $51.92M | $43.22M | $46.41M | $47.73M | $56.45M | $47.18M | $83.09M | $94.77M | $122.76M |
| Shares Outstanding | 324.81M | 308.98M | 176.14M | 150.94M | 151.82M | 148.91M | 132.11M | 127.25M | — | — |